AMCP signed on to a joint letter with other Medicare program stakeholders to HHS Secretary Azar detailing concerns with a recent Executive Order that would make changes to the anti-kickback safe harbor for manufacturer rebates and increase costs for patients.
AMCP joined with other national pharmacy stakeholders to thank HHS Secretary Azar for the agency's authorization of pharmacist administration of children's vaccines.
The leaders of 12 U.S. pharmacy organizations today issued the following statement celebrating the U.S. Department of Human Services order this week that expands the role of pharmacists in providing vaccines to children.
On August 4, 2020, CMS issued a request for information on implementation of requirements for electronic prescribing of controlled substances in Medicare Part D. Please send any feedback to advocacy@amcp.org by September 25.
This afternoon, the Trump administration released Executive Orders focused on pharmaceutical pricing. Solving this crisis and delivering real change will require elected officials and health care stakeholders to develop practical, informed, and market-based solutions that make health care and prescription drugs more affordable and accessible to all Americans.
AMCP submitted comments on a CMS proposed rule making changes to the Medicaid Drug Rebate Program to account for prescription drug value-based purchasing arrangements.
Learn about the latest health care trends and the impact of COVID-19. Here, AMCP CEO Susan A. Cantrell, RPh, CAE, highlights important analysis from last week’s webinar featuring Doug Long, vice president of industry relations at IQVIA.